232 related articles for article (PubMed ID: 34154331)
21. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
22. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer.
Daly ME; Monjazeb AM; Kelly K
J Thorac Oncol; 2015 Dec; 10(12):1685-93. PubMed ID: 26484629
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.
Passiglia F; Commendatore O; Vitali M; Conca R
Future Oncol; 2018 Jun; 14(13s):41-60. PubMed ID: 29989452
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns.
Brassart-Pasco S; Dalstein V; Brassart B; Dewolf M; Clavel C; Oudart JB
Pharmacogenomics; 2020 Jul; 21(10):705-720. PubMed ID: 32567537
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
27. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
Anagnostou VK; Brahmer JR
Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
[TBL] [Abstract][Full Text] [Related]
29. Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy.
Stinchcombe TE
Med Oncol; 2014 May; 31(5):960. PubMed ID: 24748366
[TBL] [Abstract][Full Text] [Related]
30. Treatment options after first-line immunotherapy in metastatic NSCLC.
Santos ES
Expert Rev Anticancer Ther; 2020 Mar; 20(3):221-228. PubMed ID: 32141356
[No Abstract] [Full Text] [Related]
31. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
[TBL] [Abstract][Full Text] [Related]
33. A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials.
Shaikh SS; Kumthekar PU; Mohindra NA
J Neurooncol; 2019 Aug; 144(1):235-237. PubMed ID: 31240523
[No Abstract] [Full Text] [Related]
34. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).
McCarthy F; Roshani R; Steele J; Hagemann T
J Leukoc Biol; 2013 Dec; 94(6):1201-6. PubMed ID: 23695306
[TBL] [Abstract][Full Text] [Related]
35. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
36. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
Attili I; Passaro A; Pavan A; Conte P; De Marinis F; Bonanno L
Crit Rev Oncol Hematol; 2017 Nov; 119():30-39. PubMed ID: 29065983
[TBL] [Abstract][Full Text] [Related]
37. [Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques
in the Lung Cancer Immunotherapy].
Sun W; Zhou J; Zhou J
Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):36-42. PubMed ID: 33478189
[TBL] [Abstract][Full Text] [Related]
38. What lies within: novel strategies in immunotherapy for non-small cell lung cancer.
Forde PM; Reiss KA; Zeidan AM; Brahmer JR
Oncologist; 2013; 18(11):1203-13. PubMed ID: 24105749
[TBL] [Abstract][Full Text] [Related]
39. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.
Provencio M; Carcereny E; Artal Á
Clin Transl Oncol; 2019 Nov; 21(11):1464-1471. PubMed ID: 30903517
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
